Korea Bio-Gen Co.Ltd (318000) - Total Assets
Based on the latest financial reports, Korea Bio-Gen Co.Ltd (318000) holds total assets worth ₩53.84 Billion KRW (≈ $36.49 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Korea Bio-Gen Co.Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Korea Bio-Gen Co.Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Korea Bio-Gen Co.Ltd's total assets have evolved over time, based on quarterly financial data. Check 318000 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Korea Bio-Gen Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Korea Bio-Gen Co.Ltd's total assets of ₩53.84 Billion consist of 57.5% current assets and 42.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.5% |
| Accounts Receivable | ₩4.36 Billion | 8.3% |
| Inventory | ₩8.61 Billion | 16.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩900.34 Million | 1.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Korea Bio-Gen Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Korea Bio-Gen Co.Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Korea Bio-Gen Co.Ltd's current assets represent 57.5% of total assets in 2025, an increase from 51.3% in 2017.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, up from 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 4.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 16.4% of total assets.
Korea Bio-Gen Co.Ltd Competitors by Total Assets
Key competitors of Korea Bio-Gen Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Akzo Nobel NV
AS:AKZA
|
Netherlands | €13.95 Billion |
|
Air Products and Chemicals Inc
NYSE:APD
|
USA | $41.24 Billion |
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP
|
Germany | €15.49 Billion |
|
SKC Co. Ltd
KO:011790
|
Korea | ₩6.77 Trillion |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
China | CN¥6.27 Billion |
|
Ningbo Shanshan Co Ltd
SHG:600884
|
China | CN¥45.88 Billion |
|
Jiangsu Ruitai New Energy Materials Co. Ltd.
SHE:301238
|
China | CN¥9.46 Billion |
|
5N Plus Inc.
TO:VNP
|
Canada | CA$519.27 Million |
Korea Bio-Gen Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.64 | 5.14 | 10.07 |
| Quick Ratio | 4.11 | 3.17 | 8.31 |
| Cash Ratio | 0.00 | 0.00 | 0.92 |
| Working Capital | ₩26.17 Billion | ₩22.39 Billion | ₩24.91 Billion |
Korea Bio-Gen Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Korea Bio-Gen Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.4% |
| Total Assets | ₩52.35 Billion |
| Market Capitalization | $20.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Korea Bio-Gen Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Korea Bio-Gen Co.Ltd's assets grew by 1.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Korea Bio-Gen Co.Ltd (2017–2025)
The table below shows the annual total assets of Korea Bio-Gen Co.Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩52.35 Billion ≈ $35.48 Million |
+1.37% |
| 2024-12-31 | ₩51.64 Billion ≈ $35.00 Million |
+12.38% |
| 2023-12-31 | ₩45.95 Billion ≈ $31.14 Million |
+6.68% |
| 2022-12-31 | ₩43.07 Billion ≈ $29.19 Million |
+2.56% |
| 2021-12-31 | ₩42.00 Billion ≈ $28.46 Million |
+35.19% |
| 2020-12-31 | ₩31.07 Billion ≈ $21.05 Million |
+10.34% |
| 2019-12-31 | ₩28.16 Billion ≈ $19.08 Million |
+42.20% |
| 2018-12-31 | ₩19.80 Billion ≈ $13.42 Million |
+17.84% |
| 2017-12-31 | ₩16.80 Billion ≈ $11.39 Million |
-- |
About Korea Bio-Gen Co.Ltd
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as… Read more